<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554292</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-O-A-1507</org_study_id>
    <nct_id>NCT02554292</nct_id>
  </id_info>
  <brief_title>Post Market Surveillance of SeQuent Please Neo With Scoring Balloon</brief_title>
  <acronym>PASSWORD</acronym>
  <official_title>Post MArket Surveillance of SeQuent Please Neo With ScORing Balloon Lesion Preparation in Real WorlD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Klinikum Ernst von Bergmann Augenklinik Laserzentrum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the SeQuent® Please Neo post market surveillance is to assess the
      clinical suitability of the combination of pre-dilatation using the NSE Alpha scoring balloon
      before the use of the paclitaxel-coated SeQuent® Please Neo in an 'all comer'/ 'real world'
      setting for the treatment of in-stent restenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this post market surveillance is to document the safety and efficacy of the
      drug-coated balloon Sequent® Please Neo in combination with the NSE Alpha scoring balloon in
      the treatment of in-stent restenosis following coronary stent implantation in native coronary
      arteries with reference diameters of 2.5 mm up to 4.0 mm with lesion lengths of 30 mm for
      procedural success and preservation of vessel patency
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>Target Vessel Failure</measure>
    <time_frame>9 months</time_frame>
    <description>Target Vessel Failure = TLR + Myocardial Infarction (MI) + cardiac death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>procedural success rate</measure>
    <time_frame>intraprocedural</time_frame>
    <description>lesion crossing success in in-stent restenotic lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization rate = Re-PCI + CABG(TLR)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>9 months</time_frame>
    <description>death of cardiac or unknown causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of coronary arterial bypass grafting (CABG)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of myocardial infarction</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease (CAD)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug Coated Balloon Angioplasty, Scoring Balloon Dilatation</intervention_name>
    <description>Percutaneous Coronary Intervention</description>
    <other_name>SeQuent® Please Neo Drug Coated Balloon, NSE Alpha Scoring Balloon</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with coronary artery disease, specifically with in-stent restenosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with in-stent restenosis in coronary arteries

        Exclusion Criteria:

          -  Intolerance to paclitaxel and/or the balloon coating

          -  Allergy to components of the balloon coating

          -  Pregnancy and lactation

          -  Complete occlusion of the treatment vessel

          -  Severely calcified stenosis

          -  Cardiogenic shock

          -  Risk of an intraluminal thrombus

          -  Haemorrhagic diathesis or another disorder such as gastro-intestinal ulceration or
             cerebral circulatory disorders which restrict the use of platelet aggregation
             inhibitor therapy and anti-coagulation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Bonaventura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Ernst von Bergmann</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klaus Bonaventura, MD</last_name>
    <email>kbonaventura@klinikumevb.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denny Herberger</last_name>
    <phone>+49-30-568207104</phone>
    <email>denny.herberger@bbraun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Bonaventura, MD</last_name>
      <email>kbonaventura@klinikumevb.de</email>
    </contact>
    <investigator>
      <last_name>Klaus Bonaventura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Wöhrle J, Zadura M, Möbius-Winkler S, Leschke M, Opitz C, Ahmed W, Barragan P, Simon JP, Cassel G, Scheller B. SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol. 2012 Oct 30;60(18):1733-8. doi: 10.1016/j.jacc.2012.07.040. Epub 2012 Oct 3.</citation>
    <PMID>23040575</PMID>
  </reference>
  <reference>
    <citation>Almalla M, Schröder JW, Pross V, Stegemann E, Marx N, Hoffmann R. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis. Am J Cardiol. 2011 Aug 15;108(4):518-22. doi: 10.1016/j.amjcard.2011.03.080. Epub 2011 May 31.</citation>
    <PMID>21624553</PMID>
  </reference>
  <results_reference>
    <citation>Kufner S, Cassese S, Valeskini M, Neumann FJ, Schulz-Schüpke S, Hoppmann P, Fusaro M, Schunkert H, Laugwitz KL, Kastrati A, Byrne RA; ISAR-DESIRE 3 Investigators. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial. JACC Cardiovasc Interv. 2015 Jun;8(7):877-84. doi: 10.1016/j.jcin.2015.01.031. Epub 2015 May 20.</citation>
    <PMID>26003022</PMID>
  </results_reference>
  <results_reference>
    <citation>Rittger H, Brachmann J, Sinha AM, Waliszewski M, Ohlow M, Brugger A, Thiele H, Birkemeyer R, Kurowski V, Breithardt OA, Schmidt M, Zimmermann S, Lonke S, von Cranach M, Nguyen TV, Daniel WG, Wöhrle J. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol. 2012 Apr 10;59(15):1377-82. doi: 10.1016/j.jacc.2012.01.015. Epub 2012 Feb 29.</citation>
    <PMID>22386286</PMID>
  </results_reference>
  <results_reference>
    <citation>Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K, Schulz S, Fusaro M, Ott I, Ibrahim T, Hausleiter J, Valina C, Pache J, Laugwitz KL, Massberg S, Kastrati A; ISAR-DESIRE 3 investigators. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013 Feb 9;381(9865):461-7. doi: 10.1016/S0140-6736(12)61964-3. Epub 2012 Dec 1.</citation>
    <PMID>23206837</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu B, Gao R, Wang J, Yang Y, Chen S, Liu B, Chen F, Li Z, Han Y, Fu G, Zhao Y, Ge J; PEPCAD China ISR Trial Investigators. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv. 2014 Feb;7(2):204-211. doi: 10.1016/j.jcin.2013.08.011.</citation>
    <PMID>24556098</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

